NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.
The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.
Protagen said that it recently identified autoantigen candidates in the serum of patients with prostate cancer using its UniArray technology platform. The Dortmund, Germany-based firm hopes to develop a test targeting the intermediate patient risk group, which includes individuals with a PSA range of between 2.5 ng/ml and 4.0 ng/ml.
OncoTyrol is the K1 project for Personalized Cancer Medicine and includes a consortium of researchers at the Biomedical Campus Innsbruck as well as researchers from national and international academic and industrial partners.